Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients

Mohabbat, Arya B.; Sandborn, William J.; Loftus, Edward V.; Wiesner, Russell H.; Bruining, David H.

doi:10.1111/j.1365-2036.2012.05217.x

Cited by 52 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 cases of infections were described in 3 patients (oral candidiasis, Clostridium difficile colitis, bacterial pneumonia and cryptosporidiosis). One patient had an Epstein–Barr virus positive lympho-proliferative disorder, while one death was observed because of complications from recurrent PSC [63]. Recently, a meta-analysis investigated the infection risk in 53 post-LT patients on anti-TNF-α medications compared with 23 post-LT subjects and 41 PSC-IBD not treated with anti-TNF-α.…”

Section: Liver-transplanted Patientsmentioning

confidence: 99%

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

Lopetuso

Mocci

Marzo

et al. 2018

IJMS

View full text Add to dashboard Cite

Anti-tumor necrosis factor (TNF)-α agents represent an effective treatment for chronic inflammatory diseases. However, some concerns about their potentially undesirable effects on liver function have been reported. On the other hand, evidence of their therapeutic effects on certain liver diseases is accumulating. Many data showed the safety of anti-TNF-α in patients with chronic hepatitis B and C and in liver transplanted patients even if a strict follow-up and prophylaxis are recommended in well-defined subgroups. On the other side, anti-TNF-α-induced liver injury is not a rare event. However, it is often reversible after anti-TNF-α withdrawal. Anti-TNF-α agents have been tested in advanced stages of severe alcoholic hepatitis and non-alcoholic fatty liver disease. Limited data on the efficacy of anti-TNF-α in patients with autoimmune hepatitis and primary biliary cholangitis are also available. In this review, we explored the hepatic safety concerns in patients receiving anti-TNF-α agents with and without pre-existent hepatic diseases. In addition, the available evidence on their potential benefits in the treatment of specific hepatic diseases is discussed.

show abstract

Section: Liver-transplanted Patientsmentioning

confidence: 99%

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

Lopetuso

Mocci

Marzo

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…There is limited experience regarding the long-term efficacy and safety of anti-TNF therapy in patients with OLT who are on concurrent immunosuppression. The two largest case series on the use of anti-TNF agents for management of IBD after OLT include six and eight patients, respectively 9 10. In these retrospective studies, clinical response, based on physician's global assessment, was seen in 11 out of 14 patients (78.5%).…”

Section: Discussionmentioning

confidence: 99%

Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab

Mumtaz

Goh

Hirschfield

et al. 2016

Frontline Gastroenterol

View full text Add to dashboard Cite

Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD) in approximately 70% of patients, with ulcerative colitis (UC) being the most common subtype of IBD identified. There is a paucity of data on the optimum management strategy for IBD flares in the post-liver transplant patient, particularly when refractory to conventional treatments. Vedolizumab is a novel gut-specific monoclonal antibody, which has recently been approved for use by National Institute for Health and Care Excellence for moderate-to-severe UC. We present an exemplar case of successful use of vedolizumab in the management of corticosteroid refractory PSC-IBD after liver transplantation.

show abstract

“…Besides being a signaling molecule involved in immunity, TNF is widely employed in vitro to mimic the post-transplantation signaling environment (Bogunia-Kubik et al, 2003;Brown et al, 2004;Burt et al, 2017;Mohabbat et al, 2012;Wollin et al, 2009). …”

Section: Viable High-throughput Culture Of Primary Single-cells and mentioning

confidence: 99%

Universal Microfluidic System for Analysis and Control of Cell Dynamics

Zhang

Jia

et al. 2017

Preprint

View full text Add to dashboard Cite

SUMMARYDynamical control of the cellular microenvironment is highly desired for quantitative studies of stem cells and immune signaling. Here, we present an automated microfluidic system for high-throughput culture, differentiation and analysis of a wide range of cells in precisely defined dynamic microenvironments recapitulating cellular niches. This system delivers complex, time-varying biochemical signals to 1,500 independently programmable cultures containing either single cells, 2-D populations, or 3-D organoids, and dynamically stimulates adherent or non-adherent cells while tracking and retrieving them for end-point analysis. Using this system, we investigated the signaling landscape of neural stem cell differentiation under combinatorial and dynamic stimulation with growth factors. Experimental and computational analyses identified "cellular logic rules" for stem cell differentiation, and All rights reserved. No reuse allowed without permission.

show abstract

Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients

Abstract: SUMMARY BackgroundUlcerative colitis (UC) and Crohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (OLT) despite post-transplantation immunosuppressive therapy.

Cited by 52 publications

References 19 publications

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab

Universal Microfluidic System for Analysis and Control of Cell Dynamics

Contact Info

Product

Resources

About